Gilead takes over YM BioSciences
A Gilead subsidiary acquired all YM’s outstanding common shares as per the terms of a plan of arrangement. Thus, YM has become a wholly-owned subsidiary of Gilead. YM
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.
The collaboration will focus on preclinical and clinical development of therapeutic peptide, developed by Pergamum, with both anti-infective and anti-inflammatory properties. Development activities will be carried out at